Talphera Appoints CorMedix CEO Joe Todisco to Board of Directors.

• Talphera appoints Joe Todisco as Board of Directors member • Todisco is CEO of CorMedix, which invested in Talphera in September 2025 • CorMedix has right to nominate representative to Talphera Board • CorMedix has 60-day exclusive negotiation period to acquire Talphera

Talphera, Inc. (NASDAQ: TLPH) has appointed Joe Todisco as a Class III director and member of the compensation committee, effective September 12, 2025 Talphera appoints Joseph Todisco to board, grants CorMedix board designation rights^[1]. Todisco, who currently serves as the CEO of CorMedix Inc. (NASDAQ: CRMD), brings extensive experience in the pharmaceutical industry to Talphera's board. His appointment follows a strategic investment by CorMedix in Talphera in September 2025, which granted CorMedix the right to nominate a representative to Talphera's board Talphera Announces the Appointment of Joe Todisco to Board of Directors^[2].

Todisco, 49, has held senior roles at various pharmaceutical companies, including Amneal Pharmaceuticals and Ranbaxy. He co-founded Gemini Laboratories and holds an MBA in Finance from Fordham Graduate School of Business and a BA in Economics from Georgetown University Talphera appoints Joseph Todisco to board, grants CorMedix board designation rights^[1]. His appointment includes a restricted stock unit grant and options to purchase shares of Talphera common stock, vesting over three years Talphera appoints Joseph Todisco to board, grants CorMedix board designation rights^[1].

CorMedix's strategic investment provides Talphera with financial support, while also giving CorMedix the right to designate a Talphera board member. Additionally, CorMedix has a 60-day exclusive negotiation period to acquire Talphera following the announcement of key clinical study results for Talphera's Niyad product candidate Talphera Announces the Appointment of Joe Todisco to Board of Directors^[2].

Talphera's Niyad, a lyophilized formulation of nafamostat, is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. The company has reached 25% enrollment in its NEPHRO CRRT pivotal clinical trial, with 17 out of 70 patients enrolled Talphera Announces the Appointment of Joe Todisco to Board of Directors^[2]. Talphera is navigating market challenges, including supply chain issues impacting the anticoagulation sector, and has reported strategic reductions in operating expenses Talphera appoints Joseph Todisco to board, grants CorMedix board designation rights^[1].